Selective Vulnerability of Dopaminergic Neurons — Mechanism and Protection

SUMMARY

# Selective Vulnerability of Dopaminergic Neurons — Mechanism and Protection ## Background and Rationale This mechanistic validation study employs human iPSC-derived dopaminergic neurons to investigate the molecular basis of selective vulnerability in Parkinson's disease and identify neuroprotective strategies. Dopaminergic neurons in the substantia nigra pars compacta show remarkable susceptibility to degeneration in PD, while other neuronal populations remain relatively preserved. The research

METHODOLOGY NOTES

**Phase 1: Cell Culture Preparation (Days 1-7)** • Establish primary dopaminergic neuron cultures from ventral mesencephalon of E14 rat embryos (n=200 embryos) • Plate 50,000 cells/well in 96-well plates coated with poly-L-lysine and laminin • Maintain cultures in neurobasal medium with B27 supplement, L-glutamine (2mM), and penicillin/streptomycin • Verify dopaminergic phenotype via tyrosine hydroxylase (TH) immunostaining (>80% purity required) • Include control cortical neuron cultures (n=48 wells) and astrocyte cultures (n=24 wells) **Phase 2: Oxidative Stress Induction (Days 8-10)** • Expose dopaminergic neurons to graded concentrations of 6-hydroxydopamine (6-OHDA): 10, 25, 50, 100 μM (n=12 wells/concentration) • Treat separate groups with rotenone (0.5, 1, 2.5, 5 μM) and MPP+ (250, 500, 1000 μM) (n=12 wells/concentration) • Include α-synuclein fibril treatment (1, 5, 10 μg/mL) for 24-48 hours • Monitor cell viability via MTT assay at 6, 12, 24, and 48-hour timepoints • Assess r